Agamree (Vamorolone)

AGAMREE is a medication classified as a corticosteroid, and it is prescribed to treat a medical condition called Duchenne muscular dystrophy (DMD). This medication is suitable for patients who are 2 years of age and older. Duchenne muscular dystrophy is a genetic disorder that leads to muscle weakness and deterioration.

AGAMREE works as a corticosteroid by reducing inflammation and helping to manage the symptoms associated with Duchenne muscular dystrophy. It can contribute to slowing down the progression of muscle weakness in patients with DMD, providing support to their overall muscle function.

Recommended Dosage

Before Starting AGAMREE:

• Ensure all vaccinations are up-to-date, especially live vaccines, given 4-6 weeks before starting AGAMREE.

Dosage:

• Standard: 6 mg/kg daily (max 300 mg for >50 kg).
• Some may need 2 mg/kg, adjusted based on tolerance.
• Liver issues: 2 mg/kg (max 100 mg for >50 kg).

Preparation and Administration:

• Shake oral suspension for 30 sec before use.
• Use provided oral syringe, discard unused after 3 months.

Switching from Corticosteroids:

• Switch without interruption; for long-term corticosteroid use, start AGAMREE at 6 mg/kg/day.
• With Strong CYP3A4 Inhibitors:
• Recommended: 4 mg/kg daily (max 200 mg for >50 kg).
• Adjust based on individual tolerance.

• Alterations in Endocrine Function: Chronic use of AGAMREE may lead to suppression of the hypothalamic-pituitary-adrenal axis, cushingoid features, and hyperglycemia. Patients should be closely monitored for these conditions.
• Immunosuppression and Increased Risk of Infection: There is an elevated risk of new infections, exacerbation, dissemination, or reactivation of latent infections, some of which can be severe or fatal. Signs and symptoms of infections may be obscured.
• Alterations in Cardiovascular/Renal Function: Patients on long-term AGAMREE treatment should be monitored for elevated blood pressure, and sodium and potassium levels should be regularly checked.
• Gastrointestinal Perforation: Gastrointestinal perforation, a serious condition where there is a hole or tear in the walls of the digestive tract, poses an increased risk for individuals using AGAMREE, especially those with specific gastrointestinal disorders. This risk highlights the importance of cautious monitoring, as signs and symptoms of gastrointestinal perforation might not be readily apparent. 
• Behavioral and Mood Disturbances: AGAMREE use has been associated with a spectrum of behavioral and mood disturbances, ranging from euphoria and insomnia to mood swings, personality changes, severe depression, and even psychosis. Patients and their caregivers should be vigilant in observing any alterations in mood or behavior during AGAMREE treatment. 
• Effects on Bones: Chronic use of AGAMREE may have implications for bone health, potentially impacting bone mineral density. Given the importance of maintaining skeletal strength, regular monitoring is advised for patients undergoing long-term AGAMREE treatment.
• Ophthalmic Effects: Ophthalmic complications such as cataracts, infections, and glaucoma may occur. Patients on chronic AGAMREE treatment should have their intraocular pressure monitored.
• Vaccination: Live or live attenuated vaccines should not be given to patients receiving immunosuppressive doses of corticosteroids. Such vaccines should be administered at least 4 to 6 weeks before starting AGAMREE.

If you are considering the import of Agamree (Vamorolone) to India, please be aware that Agamree can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Agamree (Vamorolone) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Agamree (Vamorolone) in India: 

Agamree (Vamorolone) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Agamree (Vamorolone) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Agamree (Vamorolone) (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements. Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Agamree (Vamorolone)  from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

What is AGAMREE® and what is it used for?

AGAMREE® is a medication containing vamorolone, a synthetic steroidal compound. It is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older. DMD is a genetic disorder leading to muscle weakness, and AGAMREE® is designed to manage its symptoms.

How does AGAMREE® work in treating Duchenne muscular dystrophy?

AGAMREE® functions as a corticosteroid by targeting the glucocorticoid receptors. It helps reduce inflammation and slow down the progression of muscle weakness associated with Duchenne muscular dystrophy.

What are the common side effects of AGAMREE®?

Common side effects of AGAMREE® include cushingoid features, psychiatric disorders, vomiting, increased weight, and vitamin D deficiency. It’s important to be aware of these potential effects and promptly report any unusual symptoms to your healthcare provider.

Can AGAMREE® be taken with other medications?

Always consult with your healthcare provider regarding potential interactions with other medications. Inform your healthcare team about all the medications, supplements, or herbal products you are currently taking to ensure safe and effective use of AGAMREE®.

Is there a specific age range for using AGAMREE®?

AGAMREE® is indicated for patients 2 years of age and older with Duchenne muscular dystrophy. It is essential to adhere to the prescribed dosage and administration guidelines provided by your healthcare professional for the specific age group and individual needs.